Can a Liver-Targeting pill help fight obesity? a new trial seeks answers

NCT ID NCT07724431

Not yet recruiting Disease control Sponsor: HongKong Curegene Innovation Co., Limited Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase 1 trial tests CG-0416, an experimental oral drug that targets thyroid hormone receptors in the liver, in healthy volunteers who are overweight or have obesity. The study aims to evaluate the drug's safety, tolerability, and how the body processes it after single and multiple doses. Researchers are looking for potential side effects and changes in hormone levels. The trial does not yet test weight loss itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CG-0416, a liver-directed thyroid hormone receptor beta agonist taken orally once daily
What this could lead to: If safe and effective, CG-0416 could become a new oral treatment option for overweight and obesity by targeting thyroid hormone pathways in the liver.
What could go wrong: This is an early phase 1 trial focused on safety, not weight loss. The drug may cause side effects or fail to show benefit in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nucleus Network Pty Ltd.

Melbourne, Victoria, 3004, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.